Huapont Life Sciences Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 27, 2021 at 09:05 am
Share
Huapont Life Sciences Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 2,819.567 million compared to CNY 2,254.687 million a year ago. Operating income was CNY 236.783 million compared to CNY 146.424 million a year ago. Net income was CNY 121.602 million compared to CNY 82.868 million a year ago. Basic earnings per share from continuing operations was CNY 0.06 compared to CNY 0.04 a year ago.
HUAPONT LIFE SCIENCES CO., LTD. is a China-based company principally engaged in the research and development, manufacture and sales of pesticide chemical products. The Company operates through three segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sales of skin pharmaceuticals, antituberculous pharmaceuticals and other manufactured products. Its products include fleroxacin and ambroxol hydrochloride for injection, and lecithin-bound iodine capsules, among others. The Pesticide Chemical segment is engaged in the production and sales of pesticides and other fine chemicals, including herbicides, bactericides and insecticides, among others. The Bulk Drug segment is engaged in the research and development and manufacture of bulk drugs and medical intermediates. The Company is also engaged in the provision of travel services, the sales of tea and the provision of technical services, among others.